Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden

Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes these drugs unattainable for most patients, and often put the health systems...

Descripción completa

Detalles Bibliográficos
Autores: Marín, Gustavo H., Marín, Lupe, Haag, Griselda, Risso, Paula, Errecalde, Jorge
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:Argentina
Institución:Comisión de Investigaciones Científicas de la Provincia de Buenos Aires
Repositorio:CIC Digital (CICBA)
Idioma:inglés
OAI Identifier:oai:digital.cic.gba.gob.ar:11746/8924
Acceso en línea:https://digital.cic.gba.gob.ar/handle/11746/8924
Access Level:acceso abierto
Palabra clave:Ciencias de la Salud
biosimilars
anaemia
chronic
failure
renal
cost
id AR_5a7bc911e6aedff28ad33bbcea57ea67
oai_identifier_str oai:digital.cic.gba.gob.ar:11746/8924
network_acronym_str AR
network_name_str Argentina
repository_id_str
spelling Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic BurdenMarín, Gustavo H.Marín, LupeHaag, GriseldaRisso, PaulaErrecalde, JorgeCiencias de la SaludbiosimilarsanaemiachronicchronicfailurerenalcostBiopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes these drugs unattainable for most patients, and often put the health systems' budgets at risk. This study takes the anaemia due to Chronic Renal Failure disease (CRFD) as an example to a rational selection of treatment with erythropoietin (EPO) and compares the trade brand mark of this drug with biosimilars option. Prescriptions of EPO in 394 patients with CRFD were submitted to a protocol of rational selection based in efficacy/risk ratio demonstration. This protocol was able to reduce that initial number to 91 cases that could really benefited with EPO treatment. These patients were included in a cohort study that compared EPO trade mark with biosimilars option. The experience demonstrated equal clinical outcomes in both groups but a reduction to half the original cost when biosimilars were dispensed. Biosimilars demonstrated to be a cheap and safe option to increase medicine access for anaemia associated to CRFD.2017-08-14info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://digital.cic.gba.gob.ar/handle/11746/8924enginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/reponame:CIC Digital (CICBA)instname:Comisión de Investigaciones Científicas de la Provincia de Buenos Airesinstacron:CICBA2024-05-10T10:38:44Zoai:digital.cic.gba.gob.ar:11746/8924Institucionalhttp://digital.cic.gba.gob.arOrganismo científico-tecnológicoNo correspondehttp://digital.cic.gba.gob.ar/oai/snrdmarisa.degiusti@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:94412024-05-10 10:38:44.488CIC Digital (CICBA) - Comisión de Investigaciones Científicas de la Provincia de Buenos Airesfalse
dc.title.none.fl_str_mv Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden
title Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden
spellingShingle Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden
Marín, Gustavo H.
Ciencias de la Salud
biosimilars
anaemia
chronic
chronic
failure
renal
cost
title_short Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden
title_full Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden
title_fullStr Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden
title_full_unstemmed Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden
title_sort Erythropoietin Treatment in Chronic Renal Failure Anaemia-Biosimilar Option in the Rational Use of Medicine Process in Order to Reduced Public Health Economic Burden
dc.creator.none.fl_str_mv Marín, Gustavo H.
Marín, Lupe
Haag, Griselda
Risso, Paula
Errecalde, Jorge
author Marín, Gustavo H.
author_facet Marín, Gustavo H.
Marín, Lupe
Haag, Griselda
Risso, Paula
Errecalde, Jorge
author_role author
author2 Marín, Lupe
Haag, Griselda
Risso, Paula
Errecalde, Jorge
author2_role author
author
author
author
dc.subject.none.fl_str_mv Ciencias de la Salud
biosimilars
anaemia
chronic
chronic
failure
renal
cost
topic Ciencias de la Salud
biosimilars
anaemia
chronic
chronic
failure
renal
cost
description Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes these drugs unattainable for most patients, and often put the health systems' budgets at risk. This study takes the anaemia due to Chronic Renal Failure disease (CRFD) as an example to a rational selection of treatment with erythropoietin (EPO) and compares the trade brand mark of this drug with biosimilars option. Prescriptions of EPO in 394 patients with CRFD were submitted to a protocol of rational selection based in efficacy/risk ratio demonstration. This protocol was able to reduce that initial number to 91 cases that could really benefited with EPO treatment. These patients were included in a cohort study that compared EPO trade mark with biosimilars option. The experience demonstrated equal clinical outcomes in both groups but a reduction to half the original cost when biosimilars were dispensed. Biosimilars demonstrated to be a cheap and safe option to increase medicine access for anaemia associated to CRFD.
publishDate 2017
dc.date.none.fl_str_mv 2017-08-14
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://digital.cic.gba.gob.ar/handle/11746/8924
url https://digital.cic.gba.gob.ar/handle/11746/8924
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:CIC Digital (CICBA)
instname:Comisión de Investigaciones Científicas de la Provincia de Buenos Aires
instacron:CICBA
instname_str Comisión de Investigaciones Científicas de la Provincia de Buenos Aires
instacron_str CICBA
institution CICBA
reponame_str CIC Digital (CICBA)
collection CIC Digital (CICBA)
repository.name.fl_str_mv CIC Digital (CICBA) - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires
repository.mail.fl_str_mv marisa.degiusti@sedici.unlp.edu.ar
_version_ 1799196480662142976
score 15.811543

Similares en LA Referencia